Novonesis reports 7% organic sales growth and 37.8% EBITDA margin in Q1 2026, confirming strong outlook.

Novonesis started 2026 with a 7% organic sales growth and a robust adjusted EBITDA margin of 37.8% in Q1, driven by growth across all sales areas and markets. The company confirmed its 2026 outlook with expected organic sales growth of 5-7% and an EBITDA margin between 37-38%. Key highlights include strong performance in Food & Health and Planetary Health Biosolutions, successful bond issuance, and acquisition of a production facility in Thailand to support expansion. Despite global uncertainties, Novonesis remains confident in achieving its long-term growth targets through continued demand for biosolutions.